Market Overview

Preview: Jazz Pharmaceuticals's Earnings


Jazz Pharmaceuticals (NASDAQ: JAZZ) announces its next round of earnings this Tuesday, August 04. Here is Benzinga's everything-that-matters guide for this Tuesday's Q2 earnings announcement.

Earnings and Revenue

Based on management's projections, Jazz Pharmaceuticals analysts model for earnings of $3.13 per share on sales of $501.95 million. In the same quarter last year, Jazz Pharmaceuticals reported EPS of $4.050 on revenue of $534.13 million. If the company were to report in-line earnings when it publishes results Tuesday, earnings would be down 22.72%. Revenue would have fallen 7.66% from the same quarter last year. Here's how the company's EPS has stacked up against analyst estimates in the past:

Quarter Q1 2020 Q4 2020 Q3 2019 Q2 2019
EPS Estimate 0.67 4.12 3.59 3.58
EPS Actual 0.45 4.42 4.10 4.05
Revenue Estimate 543.59 M 561.69 M 525.16 M 508.83 M
Revenue Actual 534.73 M 581.74 M 537.70 M 534.13 M

Stock Performance

Over the last 52-week period, shares are down 22.75%. Given that these returns are generally negative, long-term shareholders are probably down going into this earnings release.

Don't be surprised to see the stock move on comments made during its conference call. Jazz Pharmaceuticals is scheduled to hold the call at 16:30:00 ET and can be accessed here:


Related Articles (JAZZ)

View Comments and Join the Discussion!

Posted-In: Earnings